



FORM PTO-1400 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON7		SERIAL NO.: 10/057,632	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.			
				FILING DATE: January 25, 2002		GROUP: 1639	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	AD						
	AE						
	AF						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AG	The Merck Index Results, "Nimesulide," downloaded from <a href="http://themerckindex.cambridgesoft.com/TheMerckIndex/default.asp?">http://themerckindex.cambridgesoft.com/TheMerckIndex/default.asp?</a> ; downloaded on 8/10/2007.					
	AH	The Merck Index Results, "Nimesulide," downloaded from <a href="http://themerckindex.cambridgesoft.com/TheMerckIndex/default.asp?">http://themerckindex.cambridgesoft.com/TheMerckIndex/default.asp?</a> ; downloaded on 8/10/2007.					
	AI	Translation of Office Action issued in connection with Russian Federation Patent Application No. 2000109552 (November 1, 2001).					
	AJ	STN: File Registry printout of Registry Number 162054-19-5 (June 14, 2004).					
	AK	Abstract of SANTOS et al., "Antinociceptive effect of meloxicam, in neurogenic and inflammatory nociceptive models in Mice," Inflammation Research (1998), 47(7) pages 302-307, Chem. Abst. Vol. 129 (Columbus, OH)					
	AL	FRÖLICH, J.C., "A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes," TIPS, January 1997, vol. 18, pages 30-34.					
	AM	Abstract of OGINO K. et al., "Evaluation of pharmacological profile of meloxicam as an anti-inflammatroy agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1," Pharmacology 55(1):44-53, July 1997.					
	AN	Degner, Frank, et al., "Efficacy and Tolerability of Meloxicam in an Observational, Controlled Cohort Study in Patients with Rheumatic Disease", Clin Therapeutics (Nov 2000) 22: 400-410.					
	AO	Abstract of JOUZEAU J.Y. et al., "Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drus," Drugs 53(4):563-82, April 1997.					
	AP	Abstract of DVORNIK D.M., "Tissue selective inhibition of prostaglandin biosynthesis by etodolac," Journal of Rheumatology, Supplement 47:40-7, February 1997.					
	AQ	Goodman & Gillman's (1996), The Pharmacological Basis of Therapeutics, 9 <sup>th</sup> Edition, McGraw-Hill, New York pp. 654-655.					
EXAMINER		/Christopher Gross/ (11/19/2009)			DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON7		SERIAL NO.: 10/057,632	
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.			
				FILING DATE: January 25, 2002		GROUP: 1639	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINE R INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	BE						
	BF						
	BG						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	BH	Abstract of FLOWER R.J., "New directions in cyclooxygenase research and their implications for NSAID-gastropathy," Italian Journal of Gastroenterology, 28 Suppl. 4:23-7, December 1996.					
	BI	Abstract of KURUMBAIL R.G. et al., "Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents," Nature, 384(6610):644-8, December 19-26, 1996.					
	BJ	Lanes, Stephan et al., "Baseline Risk of Gastrointestinal Disorders Among New Users of Meloxicam, Ibuprofen, Diclofenac, Naproxen and Indomethacin", Pharmacoeconomics and Drug Safety (2000) 9:113-117.					
	BK	Van Hecken, Anne, et al., "Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers", J Clin Pharmacol (2000) 40: 1109-1120.					
	BL	Abstract of MASFERRER J.L. et al., "Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract," Gastroenterology Clinics of North America 25(2):363-72, June 1996.					
	BM	Richy, F., et al., "Time dependent risk of gastrointestinal complications induced by non-steroid anti-inflammatory drug use: a consensus statement using a meta-analytic approach", Ann Rheum Dis (2004) 64:759-766.					
	BN	Abstract of HOSIE J. et al., "Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium," British Journal of Rheumatology, 35 Suppl. 1:39-43, April 1996.					
	BO	Abstract of EMERY P., "Clinical implications of selective cyclooxygenase-2 inhibitor," Scandinavian Journal of Rheumatology-Supplement 102:23-8, 1996.					
	BP	Abstract of ISAKSON P. et al., "Discovery of a better aspirin," Advances in Prostaglandin, Thromboxane, & Leukotriene Research 23:49-54, 1995.					
	BQ						
EXAMINER				DATE CONSIDERED			
/Christopher Gross/ (11/19/2009)							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							